` 20B (BioMark Diagnostics Inc) vs DAX Index Comparison - Alpha Spread

B
20B
vs
D
DAX Index

Over the past 12 months, 20B has significantly outperformed DAX Index, delivering a return of +100% compared to the DAX Index's +20% growth.

Stocks Performance
20B vs DAX Index

Loading
20B
DAX Index
+19.51%
Add Stock
Created with Highcharts 11.4.8Dec '24Jan '25Feb '25Mar '25Apr '25May '25June '25July '25Aug '25Sept '25Oct '25Nov '25-25%0%25%50%75%100%125%
www.alphaspread.com

Performance Gap
20B vs DAX Index

Loading
20B
DAX Index
Difference
www.alphaspread.com

Performance By Year
20B vs DAX Index

Loading
20B
DAX Index
Add Stock

Competitors Performance
BioMark Diagnostics Inc vs Peers

BioMark Diagnostics Inc
Glance View

Market Cap
21.6m EUR
Industry
N/A

BioMark Diagnostics, Inc. engages in development and commercialization of cancer diagnostic solutions to detect, monitor, and assess treatment for cancer. The company is headquartered in Richmond, British Columbia. The company went IPO on 2014-11-03. The Company’s cancer diagnostic solutions can help detect, monitor and assess treatment for cancer. Its cancer diagnostics technology platform leverages Omics and machine learning, which allows for early cancer detection. The firm is focused on bringing its cancer diagnostic kits and detection solution to commercialization standards. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. The firm has developed a liquid biopsy metabolic panel assay. This metabolic assay is instrumental for early-stage diagnosis of lung cancer. The liquid biopsy metabolic panel has demonstrated clinical detections. The capabilities include early stage I and II Lung Cancers using urine and plasma.

20B Intrinsic Value
0.004 EUR
Overvaluation 98%
Intrinsic Value
Price
B
Back to Top